Public Citizen: Letter - Woodcock Must Be Investigated as Part of IG's Probe Into Aducanumab's Approval
July 14, 2021
July 14, 2021
WASHINGTON, July 14 (TNSPol) -- Public Citizen issued the following news release:
Acting U.S. Food and Drug Administration (FDA) Commissioner Janet Woodcock must be investigated as part of the independent investigation of the approval of aducanumab for treatment of Alzheimer's disease following the unprecedented, inappropriately close collaboration between Biogen and the agency to bring the drug to market, Public Citizen said in a letter to Christi A. Grimm, Principal Deputy Inspect . . .
Acting U.S. Food and Drug Administration (FDA) Commissioner Janet Woodcock must be investigated as part of the independent investigation of the approval of aducanumab for treatment of Alzheimer's disease following the unprecedented, inappropriately close collaboration between Biogen and the agency to bring the drug to market, Public Citizen said in a letter to Christi A. Grimm, Principal Deputy Inspect . . .